Business
Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move
Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by the end of June 2025 and will generate €8.3 ...
About this update from Cosmo Pharmaceuticals Nv
[{"type":"text","content":"Dublin, Ireland--(Newsfile Corp. - June 25, 2025) - Cosmo today announced the signing of an agreement to sell “Digital Trust” to its existing customer Tinexta InfoCert, Europe’s largest Certification Authority and a subsidiary of Tinexta S.p.A., a publicly listed company in Italy. The transaction is expected to close by the end of June 2025 and will generate €8.3 million in revenue for Cosmo.","length":419,"tagName":"p"},{"type":"text","content":"“Digital Trust” provides services within the digital security sector, offering IT solutions for digital identity protection and process dematerialization for healthcare organizations.","length":195,"tagName":"p"},{"type":"text","content":"The decision to sell “Digital Trust” is part of a broader effort to streamline the Company’s portfolio and reinforce its position as a focused, performance-driven organization. Cosmo is executing a clear strategic direction – prioritizing growth in AI-powered medical devices, gastrointestinal therapeutics, dermatology, and high-value CDMO services – while actively reallocating capital to the areas with the highest impact.","length":455,"tagName":"p"},{"type":"text","content":"“Digital Trust is not a strategic asset for Cosmo, and this transaction reflects our disciplined focus on what drives the greatest impact for patients and shareholders,” said Giovanni Di Napoli, CEO of Cosmo. “This is another concrete step forward in positioning Cosmo for sustainable growth by strengthening our focus on innovation and operational excellence in our core markets.”","length":405,"tagName":"p"},{"type":"text","content":"Cosmo continues to execute its strategy to build a focused, innovation-driven healthcare company with global reach, leveraging its strong capabilities in R&D, AI integration, and commercial partnerships.","length":207,"tagName":"p"},{"type":"text","content":"About Cosmo Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution ...